A leader in clinical research on dementia in China who guards the “soul of memory”——Professor Jia Jianping

doi:10.3969/j.issn.1006-7795.2020.05.019

Abstract

Abstract: He has been devoting himself to the dream of "protecting memory and keeping the beauty of the world". He led the team to overcome the challenges to dementia and found a marker that can predict memory declines 5-7 years before the onset of symptoms, which provided precious chance of early prevention. In order to set up dementia treatment guidelines suitable for Chinese, he made great efforts to explore the occurrence and progress of dementia, epidemiology of dementia and the genetic rules of dementia in China. He has reported the "blowout phenomenon"(more than 40 million) in the number of memory disorders caused by ageing among Chinese population for the first time, and also pointed out that dementia could be prevented by controlling the risk factors. The focus of his research has been on the genetic pattern of dementia in Chinese and the possibility of early intervention in dementia patients carrying risk genes, and he reported pathogenic gene mutations in Chinese for the first time and proposed the genetic intervention strategies. To establish the animal models for development of anti-dementia drugs in China, he has constructed 10 new Alzheimer's disease animal models based on Chinese genetic variations, which highlighted the research spirit of self-reliance. To standardize the clinical practice of dementia and cognitive impairment in China, he was in charge of establishing the 2010 and 2015 editions of the "Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment in China", and published 23 articles, which greatly advanced the level of clinical diagnosis and treatment of dementia in China. In addition, he has led more than 20 clinical trials to develop the new anti-dementia drugs. He discovered two new drugs DL-3-n-butylphthalide and Sailuotong which showed a positive effect on vascular dementia. This achievement attracted attention of scholars in China and oversea. He and his group have immersed themselves in the exploration to prevent dementia in China and have taken a leading role in anti-dementia worldwide. The man is Professor Jia Jianping.

Key words: Alzheimer's disease, dementia, biomarker, animal models, guidelines

CLC Number:

R741.05

Li Yan. A leader in clinical research on dementia in China who guards the “soul of memory”——Professor Jia Jianping[J]. Journal of Capital Medical University, 2020, 41(5): 822-827.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2020.05.019

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2020/V41/I5/822

References

[1] Jia J, Zhou A, Wei C, et al. The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese[J]. Alzheimers Dement, 2014, 10(4):439-447.
[2] Jia J, Wang F, Wei C, et al. The prevalence of dementia in urban and rural areas of China[J]. Alzheimers Dement, 2014, 10(1):1-9.
[3] Jia J, Wei C, Chen S, et al. The cost of Alzheimer's disease in China and re-estimation of costs worldwide[J]. Alzheimers Dement, 2018, 14(4):483-491.
[4] Jia J, Zuo X, Jia X F, et al. Diagnosis and treatment of dementia in neurology outpatient departments of general hospitals in China[J]. Alzheimers Dement, 2016, 12(4):446-453.
[5] Jia L, Quan M, Fu Y, et al. Dementia in China:epidemiology, clinical management, and research advances[J]. Lancet Neurol, 2020, 19(1):81-92.
[6] Jia L, Du Y, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in China:a national cross-sectional study on 46011 adults ≥ 60 in 2015-2018[J]. Lancet Public Health, 2020.(Accepted)
[7] 贾建平. 中国痴呆与认知障碍诊治指南(2010年版)[M].北京:人民卫生出版社,2010.
[8] 贾建平. 中国痴呆与认知障碍诊治指南(2015年版)[M]. 北京:人民卫生出版社,2016.
[9] Jia J, Gauthier S, Pallotta S, et al. Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease[J]. Alzheimers Dement, 2017, 13(5):592-597.
[10] Jia J, Xu E, Shao Y, et al. One novel presenilin-1 gene mutation in a Chinese pedigree of familial Alzheimer's disease[J]. J Alzheimers Dis, 2005, 7(2):119-124; discussion 173-180.
[11] Jia L, Fu Y, Shen L, et al. PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer's disease[J]. Alzheimer's Dement, 2020, 16(1):178-191.
[12] Jia L, Li F, Wei C, et al. Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study[J]. Brain, 2020.DOI:10.1093/brain/awaa364
[13] Jia L, Xu H, Chen S, et al. The APOE-ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease[J]. Alzheimers Dement, 2020. DOI:10.1002/alz.12153.
[14] Jia L, Qiu Q, Zhang H, et al. Concordance between the assessment of Abeta42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid[J]. Alzheimers Dement, 2019, 15(8):1071-1080.
[15] Jia L, Zhu M, Kong C, et al. Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage[J]. Alzheimers Dement, 2020.
[16] Jia J, Wei C, Liang J, et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease:a multicentre, randomized, double-blind, placebo-controlled trial[J]. Alzheimers Dement, 2016,12(2):89-99.
[17] Jia J, Wei C, Chen S, et al. Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia:a randomized clinical trial[J]. Alzheimers Dement (N Y), 2018, 4:108-117.